Safety and Efficacy of Lorundrostat in Uncontrolled Hypertension: A Systematic Review and Meta-analysis
- 6 July 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 88 (5) , 355-363
Abstract
Uncontrolled hypertension remains a major global health concern and a leading cause of cardiovascular morbidity and mortality. Aldosterone dysregulation plays a critical role in resistant hypertension, and lorundrostat, a novel aldosterone synthase inhibitor, offers a promising therapeutic approach by directly inhibiting aldosterone production. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of lorundrostat in adults with uncontrolled hypertension. Comprehensive searches of MEDLINE (PubMed), ScienceDirect, Google Scholar, and Cochrane databases were conducted up to July 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with the protocol registered on PROSPERO (CRD420251091117). Three randomized controlled trials involving 1568 participants (1165 lorundrostat and 403 placebo) were included, all demonstrating low risk of bias. Pooled analysis revealed that lorundrostat significantly reduced systolic blood pressure (BP) (−8.50 mm Hg, 95% confidence interval: –11.63 to −5.36, P < 0.00001) and diastolic BP (−3.53 mm Hg, 95% confidence interval: –5.61 to −1.45, P = 0.0009) compared with placebo, with no heterogeneity observed. However, lorundrostat was associated with higher risks of hyperkalemia (RR = 5.84, P = 0.01), symptomatic hypotension (RR = 2.98, P = 0.03), serious adverse events (RR = 3.31, P = 0.03), and hyponatremia (RR = 2.03, P = 0.01), although there were no significant differences in moderate or severe adverse events or reduction in kidney function. Publication bias was noted for diastolic BP and selected safety outcomes. In conclusion, lorundrostat demonstrates clinically meaningful BP reduction in uncontrolled hypertension compared with placebo, but with an increased risk of electrolyte disturbances and hypotension. Cautious use and close monitoring are warranted, and larger, long-term trials are needed to further define its safety and therapeutic role.Keywords
This publication has 29 references indexed in Scilit:
- Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant HypertensionJAMA, 2025
- Global Burden of Cardiovascular Diseases and Risks, 1990-2022JACC, 2023
- Hypertension and Lorundrostat: Key Discoveries From the TARGET-HTN TrialCurrent Problems in Cardiology, 2023
- Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled HypertensionJAMA, 2023
- Current and Emerging Classes of Pharmacological Agents for the Management of HypertensionAmerican Journal of Cardiovascular Drugs, 2021
- Incidence, Predictors and Clinical Management of Hyperkalaemia in New Users of Mineralocorticoid Receptor AntagonistsEuropean Journal of Heart Failure, 2018
- Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2018
- A meta-analysis of add-on use of spironolactone in patients with resistant hypertensionInternational Journal of Cardiology, 2017
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialThe Lancet, 2015
- Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: Systematic review and meta-analysisInternational Journal of Cardiology, 2014